Increlex
What Increlex is used for
For the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary IGFD). Severe primary IGFD is defined by: height standard deviation score … (the exact criteria are in the official EMA product information).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Increlex
- Active substance
- mecasermin
- Disease area
- Laron Syndrome
- Medicine group
- Pituitary and hypothalamic hormones and analogues
- ATC code
- H01AC03
- Marketing authorisation holder
- Esteve Pharmaceuticals, S.A.
- Authorised in the EU since
- 2007
Official information
In the USA
Same active substance: Increlex
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Increlex used for?
For the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary IGFD). Severe primary IGFD is defined by: height standard deviation score … (the exact criteria are in the official EMA product information).
What is the active substance in Increlex?
Increlex contains mecasermin.
Who makes Increlex?
The EU marketing authorisation holder is Esteve Pharmaceuticals, S.A..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU